CO2017002472A2 - Abiraterone acetate formulation - Google Patents

Abiraterone acetate formulation

Info

Publication number
CO2017002472A2
CO2017002472A2 CONC2017/0002472A CO2017002472A CO2017002472A2 CO 2017002472 A2 CO2017002472 A2 CO 2017002472A2 CO 2017002472 A CO2017002472 A CO 2017002472A CO 2017002472 A2 CO2017002472 A2 CO 2017002472A2
Authority
CO
Colombia
Prior art keywords
abiraterone acetate
acetate formulation
formulation
compositions
producing
Prior art date
Application number
CONC2017/0002472A
Other languages
Spanish (es)
Inventor
Maura Murphy
Paul Nemeth
H William Bosch
Matthew Callahan
Satya Bhamidipati
Jason Coleman
Christopher Hill
Marck Norret
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017002472(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of CO2017002472A2 publication Critical patent/CO2017002472A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

La presente presenta composiciones farmacéuticas, que incluyen formas de dosificación unitarias, que comprenden acetato de abiraterona, así como también métodos para producir y usar dichas composiciones como se describe.The present presents pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate, as well as methods for producing and using such compositions as described.

CONC2017/0002472A 2014-09-18 2017-03-15 Abiraterone acetate formulation CO2017002472A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
CO2017002472A2 true CO2017002472A2 (en) 2017-07-11

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0002472A CO2017002472A2 (en) 2014-09-18 2017-03-15 Abiraterone acetate formulation

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102617537B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2018000318A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
CN118766866A (en) 2017-04-07 2024-10-15 玛亚实验室公司 Methods for improving solubility and bioavailability of therapeutic agents
CN113473974A (en) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 Pharmaceutical composition
IL286048B1 (en) 2019-03-06 2024-11-01 Propella Therapeutics Inc Abiraterone decanoate and pharmaceutically acceptable salts thereof, pharmaceutical compsitions comprising the same, uses and preparation thereof
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
KR20230008783A (en) * 2020-05-08 2023-01-16 얀센 파마슈티카 엔.브이. Pharmaceutical Formulations of Abiraterone Acetate and Niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CA3207282A1 (en) 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone
KR20240145412A (en) 2023-03-27 2024-10-07 한미약품 주식회사 Pharmaceutical formulation comprising abiraterone acetate and prednisolone and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107049957A (en) * 2009-04-24 2017-08-18 伊休蒂卡有限公司 The nano particle of encapsulating is prepared plant-scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (en) 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
PL3578266T3 (en) 2013-03-15 2024-10-21 Sun Pharmaceutical Industries Limited Abiraterone acetate formulation

Also Published As

Publication number Publication date
JP2017528457A (en) 2017-09-28
SG11201701139YA (en) 2017-03-30
MX2017003525A (en) 2017-06-21
IL250270B (en) 2021-02-28
TN2018000318A1 (en) 2020-01-16
BR112017003219A2 (en) 2017-11-28
AU2015317466A1 (en) 2017-02-23
EP3193857A4 (en) 2018-04-11
KR20170070025A (en) 2017-06-21
PH12017500239A1 (en) 2017-07-03
EA201790650A1 (en) 2017-07-31
KR102491439B1 (en) 2023-01-25
KR20230014878A (en) 2023-01-30
MD20170048A2 (en) 2017-08-31
WO2016044701A1 (en) 2016-03-24
KR102617537B1 (en) 2023-12-22
AP2017009804A0 (en) 2017-03-31
EP3193857A1 (en) 2017-07-26
CA2958316A1 (en) 2016-03-24
CN106687112A (en) 2017-05-17
TN2017000098A1 (en) 2018-10-19
IL250270A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CO2017002472A2 (en) Abiraterone acetate formulation
BR112015023629A8 (en) ABIRATERONE ACETATE FORMULATION
MX2023008686A (en) Modulatory polynucleotides.
BR112018010211A2 (en) aqueous pharmaceutical formulation comprising anti-pd-l1 avelumab antibody
CL2016002772A1 (en) Fast-acting insulin compositions
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CL2016001609A1 (en) Pharmaceutical compositions comprising azd9291.
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
MX2015009058A (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
SV2017005412A (en) COMPOUNDS OF 1-RENT-6-OXO-1,6-DIHIDROPIRIDIN-3-ILO AND USES OF THE SAME
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
BR112017001221A2 (en) indolizine derivatives that are applicable to neurodegenerative diseases
EP3149035A4 (en) Therapeutic compositions including therapeutic small molecules and uses thereof
DOP2017000058A (en) TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMINUM INHIBITORS
IL252897A0 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
GT201600252A (en) NAFTIRIDINADIONA DERIVATIVES
CO2017007316A2 (en) Pharmaceutical formulation
BR112016028083A2 (en) ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN AND ITS PREPARATION PROCESS
BR112017024126A2 (en) pharmaceutical compositions and use thereof
MX2015016603A (en) Corticosteroid compositions.
CR20160322A (en) HEXAHYDROFUROPIRROLES AS PDE1 INHIBITORS
BR112016020135A2 (en) compound mixture, its uses, pharmaceutical composition, and set (kit)
GT201600190A (en) CHEMICAL COMPOUNDS
UA106905U (en) Pharmaceutical formulation
MX2016001694A (en) Saccharide vaccine formulation.